Screener
Generate Biomedicines, Inc. GENB Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Generate Biomedicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Generate Biomedicines, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336437
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development(1) | 64,330 | 59,735 | 122,142 | 106,560 |
| General and administrative(2) | 13,598 | 10,545 | 27,122 | 20,692 |
| Total operating expenses | 77,928 | 70,280 | 149,264 | 127,252 |
| Loss from operations | (71,614) | (60,150) | (135,726) | (108,304) |
| Other income (expense), net | ||||
| Change in fair value of convertible preferred stock warrant liability | — | — | (363) | — |
| Interest expense | (155) | (307) | (337) | (675) |
| Interest income | 4,629 | 3,789 | 7,542 | 8,070 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Generate Biomedicines, Inc.'s operating income?
- Generate Biomedicines, Inc. (GENB) reported operating income of -$71.61M in Q2 2026.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Generate Biomedicines, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude